Literature DB >> 2552909

Continuous infusion of high-dose acyclovir for serious herpesvirus infections.

C V Fletcher1, J A Englund, B Bean, B Chinnock, D M Brundage, H H Balfour.   

Abstract

Thirteen patients with herpesvirus infections who were unresponsive to at least 72 h of intermittent acyclovir administration received high-dose continuous infusion. Steady-state concentrations were maintained at between 20 and 98 mumol/liter. Of 12 patients who had continuous infusion for greater than 5 days, 7 (58%) resolved their infections, as determined by clinical and virologic parameters, suggesting that continuous infusion may succeed in some patients who do not respond to conventional therapy.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2552909      PMCID： PMC172658          DOI： 10.1128/AAC.33.8.1375

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

2.  Severe, progressive herpetic whitlow caused by an acyclovir-resistant virus in a patient with AIDS.

Authors:  S A Norris; H A Kessler; K H Fife
Journal:  J Infect Dis       Date:  1988-01       Impact factor: 5.226

3.  Progressive mucocutaneous herpes simplex infection due to acyclovir-resistant virus in an immunocompromised patient: correlation of viral susceptibilities and plasma levels with response to therapy.

Authors:  B Bean; C Fletcher; J Englund; S N Lehrman; M N Ellis
Journal:  Diagn Microbiol Infect Dis       Date:  1987-07       Impact factor: 2.803

4.  Neurotoxicity due to adenine arabinoside therapy during varicella-zoster virus infections in immunocompromised children.

Authors:  S Feldman; P K Robertson; L Lott; D Thornton
Journal:  J Infect Dis       Date:  1986-11       Impact factor: 5.226

5.  A program package for simulation and parameter estimation in pharmacokinetic systems.

Authors:  D Z D'Argenio; A Schumitzky
Journal:  Comput Programs Biomed       Date:  1979-03

6.  Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation.

Authors:  D W Hanto; G Frizzera; K J Gajl-Peczalska; K Sakamoto; D T Purtilo; H H Balfour; R L Simmons; J S Najarian
Journal:  N Engl J Med       Date:  1982-04-15       Impact factor: 91.245

Review 7.  Virus resistance in clinical practice.

Authors:  C Dekker; M N Ellis; C McLaren; G Hunter; J Rogers; D W Barry
Journal:  J Antimicrob Chemother       Date:  1983-09       Impact factor: 5.790

8.  Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts.

Authors:  A Erice; M C Jordan; B A Chace; C Fletcher; B J Chinnock; H H Balfour
Journal:  JAMA       Date:  1987-06-12       Impact factor: 56.272

Review 9.  Overview of acyclovir pharmacokinetic disposition in adults and children.

Authors:  M R Blum; S H Liao; P de Miranda
Journal:  Am J Med       Date:  1982-07-20       Impact factor: 4.965

10.  A sensitive radioimmunoassay for the antiviral agent BW248U [9-(2-hydroxyethoxymethyl)guanine].

Authors:  R P Quinn; P de Miranda; L Gerald; S S Good
Journal:  Anal Biochem       Date:  1979-10-01       Impact factor: 3.365
View more
  6 in total

1.  Famciclovir for the management of genital herpes simplex in patients with inadequate response to aciclovir or valaciclovir.

Authors:  Stephen L Sacks; Fred Y Aoki
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

Review 2.  Drug treatment of HIV-related opportunistic infections.

Authors:  M E Klepser; T B Klepser
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

3.  Continuous infusion of acyclovir is more effective than discontinuous infusion for treatment of genital herpes in an immunocompromised patient.

Authors:  L Mock; L Dossou-Gbété; M Merle-Melet; A Gérard
Journal:  Infection       Date:  1994 Jul-Aug       Impact factor: 3.553

Review 4.  Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  A J Wagstaff; D Faulds; K L Goa
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

Review 5.  Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology.

Authors:  Charlotte I S Barker; Eva Germovsek; Rollo L Hoare; Jodi M Lestner; Joanna Lewis; Joseph F Standing
Journal:  Adv Drug Deliv Rev       Date:  2014-01-17       Impact factor: 15.470

6.  Population Pharmacokinetics of Intravenous Acyclovir in Oncologic Pediatric Patients.

Authors:  Natalia Maximova; Daniela Nisticò; Giacomo Luci; Roberto Simeone; Elisa Piscianz; Ludovica Segat; Egidio Barbi; Antonello Di Paolo
Journal:  Front Pharmacol       Date:  2022-04-14       Impact factor: 5.988
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.